Placebo response and remission rates in randomized trials of induction and maintenance therapy for ulcerative colitis

Vipul Jairath*, G. Y. Zou, Claire E. Parker, John K. Macdonald, Turki Alameel, Mohammad Al Beshir, Majid A. Almadi, Talal Al-Taweel, Nathan S.S. Atkinson, Sujata Biswas, Thomas Chapman, Parambir S. Dulai, Mark A. Glaire, Daniël R. Hoekman, Andreas Koutsoumpas, Elizabeth Minas, Mahmoud H. Mosli, Mark Samaan, Margaret K. Vandervoort, Simon TravisGeert D'Haens, Barrett G. Levesque, William J. Sandborn, Brian G. Feagan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: The objective of this review is to identify the factors that contribute to placebo response and remission rates in induction and maintenance trials of UC in which patients with active or quiescent disease were enrolled using the UCDAI.

Original languageEnglish (US)
Article numberCD011572
JournalCochrane Database of Systematic Reviews
Volume2015
Issue number3
DOIs
StatePublished - Mar 9 2015
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Placebo response and remission rates in randomized trials of induction and maintenance therapy for ulcerative colitis'. Together they form a unique fingerprint.

Cite this